T&L Co., Ltd. (340570.KQ)

Deep Dive Research Report | 5 September 2026

A note on reporting cadence and sources, before anything else

T&L has a 31 December fiscal year end and reports quarterly under Korean rules, with a 45-day filing deadline. The most recent reporting period that should exist as of today is Q2/H1 2026, due by 14 August 2026. It exists: the semi-annual report was filed to DART on 14 August 2026, and the same date appears on the exchange earnings calendar for the period ending 06/2026 (IRGO filing list; Investing.com earnings calendar). The next scheduled release is Q3 2026 on 12 November 2026.

T&L does not hold public quarterly earnings conference calls and publishes no transcripts. This is normal for a KOSDAQ small cap and it is a real limitation of this report, stated plainly rather than papered over. What exists instead, and what Sections 7 and 9 are built from, is: (a) the DART quarterly, semi-annual and annual filings; (b) periodic investor briefings filed as 기업설명회(IR) 개최 notices to KRX KIND, plus domestic non-deal roadshows (per the company's IRGO page: NDRs on 26-27 May 2025 and 9 September 2025, and an IR session on 7 April 2026 in Yeouido); (c) sell-side notes written directly off those company meetings, which in Korea function as the closest available proxy for a call transcript; and (d) attributed statements from the CEO and company spokespeople in the Korean trade press. Every forward-looking claim below is tied to one of those, with its date.

The six reporting periods used throughout are:

1. What the company does

T&L makes the sticky, translucent gel-and-film material that goes on a wound so it heals faster and scars less. Then it cuts that material into shapes, sterilises it, packs it, and ships it to other companies who put their own brand on the box.

That is genuinely the whole business, and understanding why it is a good business requires understanding two things: what the material is, and who owns the box.

The material is hydrocolloid. It is a composite: a mix of water-absorbing polymer particles (typically carboxymethyl cellulose, pectin, gelatin) suspended in a rubbery, tacky adhesive matrix, laminated onto a thin polyurethane backing film. Stick it on a wound and the particles absorb the exudate the wound is leaking, swell into a soft gel, and hold that gel against the wound bed. The backing film keeps bacteria and dirt out but lets some water vapour through. The result is a sealed, moist environment. Wounds heal materially faster in moist conditions than under a dry gauze, and they scar less, because the new tissue does not have to grow through a scab.

The consumer version of this insight is the acne patch. Put a small hydrocolloid dot on a pimple that has come to a head and it pulls the fluid out, flattens the lesion, and stops you picking at it. It looks like nothing; it works; it is cheap. This is the single product that turned T&L from a modest Korean medical-materials supplier into a company whose factory output shows up in US customs data.

Who owns the box is the other half. T&L does not own the brand a US consumer buys. It is an ODM: it develops and manufactures the product to a customer's specification, and the customer puts its name on it. The customer, overwhelmingly, is Hero Cosmetics, whose Mighty Patch is the acne patch that has repeatedly ranked at or near the top of Amazon's Beauty & Personal Care bestseller list in the US (Newsis, 25 May 2021). Hero was acquired by Church & Dwight for $630 million in September 2022 (Church & Dwight press release, 6 Sept 2022), which put Mighty Patch behind the shelf access of a company that also sells Arm & Hammer, Trojan and OxiClean. Every Mighty Patch sold in a US Target or a UK Boots was made in Anseong, Gyeonggi Province.

The founding story, and why it explains the company

T&L was founded in 1998 by Choi Yoon-so (최윤소), who remains CEO and controlling shareholder. Per the Business Post profile of him, he was born on 1 February 1959, took a bachelor's degree in textile engineering at Sungkyunkwan University, and then a master's and a doctorate at the Tokyo Institute of Technology. The same profile records him as a researcher at RIKEN, Japan's Institute of Physical and Chemical Research, from 1991 to 1992, and at the central research laboratory of Dongsung Chemical from 1992 to 1998, before he left during the Asian financial crisis and started T&L (Business Post, "Who Is? 최윤소 티앤엘 대표이사"). Details of his career before 1991 are not disclosed in the sources reviewed.

That background matters more than founder biographies usually do. T&L did not start as a medical device company that later learned chemistry. It started as a polymer chemistry company that later found medical applications. Its first business was orthopaedic fixation material: casts and splints, the fibreglass-and-resin sleeves that replaced plaster of Paris. Per an iTooza profile at the time of the IPO, the company developed what it described as an environmentally friendly fracture-fixation material in 1999 (iTooza, 11 Nov 2020). Casting tape is a resin problem: you need a polymer that is inert and workable when dry, cures fast and hard on contact with water, does not exotherm enough to burn a patient's skin, and can be wound onto a limb by a nurse in ninety seconds.

The pivot to wound care came out of the same materials capability. T&L developed hydrocolloid domestically, replacing imported product, and describes itself as the first Korean company to do so; The Scoop dates the development to 2007 (The Scoop, "시크한 분석: 티앤엘"). The company synthesises the base chemistry itself rather than buying compounded material, which is where its cost position comes from.

The core value proposition

If you are a consumer brand that wants to sell an acne patch, or a pharmaceutical company that wants a wound dressing line, you have three options. Buy finished patches from a trading company and accept whatever the material is. Buy compounded hydrocolloid from a chemical supplier and pay someone else to convert it. Or go to a company that owns the formulation and the conversion line and can move both.

T&L is the third. The formulation is the leverage. Choi has described hydrocolloid as having more than twenty separately controllable variables, which is what lets the company tune a sheet for a different customer's requirement (Business Post profile). That is not marketing. Adhesion, absorbency, swelling rate, clarity when wet, edge lift, conformability, thickness, moisture vapour transmission rate, residue on removal, and shelf stability all trade off against each other, and a brand asking for "thinner but still absorbs as much and does not turn white" is asking for a reformulation, not a spec change.

"T&L constantly strives to maximize customer satisfaction through superior quality and service based on eco-friendly, cutting-edge technology."

• Choi Yoon-so, quoted in the Business Post profile

The quote is corporate. The operative word inside it, for anyone reading the business, is "service": in ODM, the thing you sell after the material is your willingness to reformulate on somebody else's timetable.

A concrete example: how a Mighty Patch actually gets made

Walk it through end to end.

1. The brief. Hero, now inside Church & Dwight, specifies a product: dot diameter range, thickness, target absorbency, clarity, adhesion on facial skin, wear time overnight, and a target landed cost per patch that has to survive a US mass-retail price point.
2. Formulation. T&L's Anseong research group builds a hydrocolloid compound to the brief. This is iterative and it is where the twenty-odd variables get traded against each other.
3. Compounding and casting. The polymer matrix and the hydrophilic particles are mixed and cast as a continuous layer onto a polyurethane backing film, with a release liner on the adhesive face. This is a coating line: web speed, gap, temperature and cure profile determine whether the sheet is uniform. Non-uniformity shows up as inconsistent absorbency, which shows up as a consumer complaint about a patch that "does not work".
4. Die-cutting. The web is kiss-cut into dots of several diameters. Yield here is a real cost line, because the skeleton around the dots is waste.
5. Packing and sterilisation. Dots are laid onto carrier sheets, sealed, and sterilised to the standard required by the destination market's regulator.
6. Export. Product ships from Korea to the US and, increasingly, to Europe. Wound-dressing exports from Anseong are visible in Korean customs data at the city level, which is how analysts track T&L's shipment run rate month by month.
7. Distribution. Church & Dwight's sales organisation puts the product into Target, Walmart, CVS and Amazon, runs the marketing, and takes the retail margin. Hero has been advertised in the Super Bowl.

T&L's name appears nowhere in that last step. That is the trade: enormous operating leverage on a factory in Gyeonggi Province, and no control over the demand that fills it.

2. Business segments

T&L is not a conglomerate, but it is meaningfully more than one business, and the segments have genuinely different economics. Revenue mix percentages below are drawn from the sources cited; the company's disclosure granularity changes between years, so the two anchor points are stated separately rather than blended.

Two documented mix snapshots:

• FY2023 basis (cited in the iM Securities analysis reproduced by The Scoop): hydrocolloid wound dressing roughly 66%, polyurethane foam wound dressing roughly 10%, microneedle roughly 9%, orthopaedic fixation and other roughly 15%.
• 2024-2026 basis: wound care in aggregate reached roughly 84% of company revenue on the 2024 provisional figures (The Scoop), and Hana Securities put hydrocolloid alone at roughly 75% of revenue in an April 2026 note, with orthopaedic fixation around 10% (Newspim report brief, 14 Apr 2026).

The direction of travel is unambiguous: hydrocolloid has been eating the mix.

2.1 Hydrocolloid wound dressing (the engine)

What it does. This is the trouble-care and acne patch business plus conventional hydrocolloid wound dressings. The consumer patch line is sold almost entirely through ODM to Hero/Church & Dwight under the Mighty Patch name, plus a domestic and export dressing line under T&L's own RenoCare brand. RenoCare is positioned as an occlusive moist-environment dressing for light wounds and abrasions, sold to pharmacies, hospitals and distributors.

The core capability. Formulation ownership plus conversion. T&L synthesises and compounds its own hydrocolloid rather than buying it, which is the origin of its cost advantage, and it runs the casting and die-cutting lines. It was the first Korean developer of hydrocolloid, displacing imports. Third-party trade listings describe T&L as holding above 60% share of Korean hydrocolloid roll raw material.

Why it is a segment. It is the only part of the company whose demand is consumer-driven rather than clinical or industrial. Its volume responds to a US retail marketing calendar, not to hospital procurement cycles. That is why the 2025 downturn in this segment was an inventory event at one customer rather than anything that happened in a hospital.

Competitive position. Against global advanced-wound-care majors, T&L does not compete in the clinical dressing category on brand or on hospital sales force. It competes in the consumer trouble-patch category, where it is the manufacturing backbone of the category leader. Against Korean rivals it has the deepest hydrocolloid position; against other Asian ODMs it has the qualified US and EU regulatory footprint and the reference customer.

How management treats it. As the business. Everything else in the company is discussed relative to whether it reduces dependence on this.

2.2 Polyurethane foam and other advanced dressings

What it does. Foam dressings for deeper and higher-exudate wounds, burns and ulcers, sold under the RenoFoam brand and through ODM. T&L also holds hydrogel, alginate and silicone dressing technology, plus scar-management silicone gel sheets. This is the clinical end of the portfolio: pharmacies, hospitals, distributors, and named pharmaceutical partners.

The core capability. Foam is a different polymer problem to hydrocolloid. You are engineering an open-cell polyurethane structure with controlled pore size and wicking, laminated with a semi-permeable top film, sometimes with a silicone contact layer so it does not rip granulation tissue on removal. It took the company from a resin base into a foam base.

Why it is a segment. Different clinical indication, different buyer (clinician and hospital procurement, not a consumer brand manager), different regulatory class, and different competitive set. Foam puts T&L up against Mölnlycke, Smith+Nephew and, domestically, Genewel's Medifoam.

Competitive position. This is the segment where T&L is a challenger rather than an incumbent. The global foam category is dominated by companies with hospital sales organisations that T&L does not have. Domestically Medifoam is the established brand. T&L's route into foam has been ODM and material supply rather than clinical brand-building.

How it fits. It is portfolio breadth and a hedge, roughly a tenth of revenue on the FY2023 basis. It is not the growth bet and management does not present it as one.

2.3 Microneedle patches

What it does. Dissolving microneedle patches: an array of needles tens to hundreds of micrometres long, moulded from a soluble matrix loaded with an active ingredient, pressed onto skin so the needles dissolve and deliver the active below the stratum corneum. T&L's application is early-stage acne, ahead of the point where a hydrocolloid patch becomes useful. The Scoop dates T&L's microneedle development to 2022.

The customer split here is instructive. In the US, microneedle patches went to Hero under an exclusive arrangement. Domestically, T&L's microneedle technology is sold through Dongkook Pharmaceutical, which markets it as the Madeca ArcQ Spot Patch (pharm.edaily, 15 Apr 2024).

The core capability. Moulding a needle array at micron scale, at consumer-goods cost, without breaking needles in handling or losing potency in storage. The manufacturing constraint is throughput: microneedle lines are slower than coating lines, which is why capacity expansion here is discussed as a discrete project rather than a line-speed adjustment.

Why it is a segment. Different production process entirely, different capacity constraint, different regulatory pathway when the payload is a drug rather than a cosmetic active, and a different competitive set that includes specialist microneedle houses.

Competitive position. Contested. Raphas is the best-known listed Korean microneedle specialist and has pursued the US acne patch market with its own branded OTC drug patches and its own manufacturing approach. Daewoong Therapeutics has a separate microneedle platform. T&L's advantage is that it can bundle microneedle with the hydrocolloid it already sells the same customer; its disadvantage is that it is not the deepest microneedle IP holder in Korea.

How it fits. Management has consistently framed microneedle as the next growth engine. It was roughly 9% of revenue on the FY2023 basis, and capacity here was doubled in 2024.

2.4 Orthopaedic fixation materials

What it does. Casts and splints, the original business. Sold to hospitals and distributors domestically and on export.

The core capability. Water-cured resin chemistry on a knitted fibreglass substrate, and the process control to make it set predictably.

Why it is a segment. It is the founding business, it shares almost nothing operationally with the dressing lines, and its customers are orthopaedic departments. It also provides a reason for the company to exist inside hospital procurement systems at all.

Competitive position. Mature, commoditised, competitive on price and distribution. Not where the company differentiates.

How it fits. Roughly a tenth of revenue. It is a cash-generative legacy that is now heavily diluted in the mix by hydrocolloid growth. Management does not present it as a growth priority.

2.5 Chemical materials

What it does. The upstream chemistry the company never left. Per the company profile carried on Yahoo Finance, T&L's chemical products include waterborne resins, hardeners, functional additives and urethane foam. Waterborne polyurethane, waterborne urethane-acrylate, waterborne acrylic polyol and waterborne polyisocyanate hardeners are sold into coatings and paints.

The core capability. This is not a side business; it is the foundation. The medical products are downstream applications of the same polymer chemistry.

Why it is a segment. Industrial customers, industrial pricing, no medical regulatory burden.

Competitive position. A small player in a large, competitive industrial chemicals market. It is not a source of differentiation.

How it fits. Small in revenue, structurally important as capability. It is the reason the company can say it makes its own raw material, which is the sentence that underwrites the cost position in the patch business.

2.6 Europe, CBD and own-brand cosmetics (the option)

What it does. T&L established a European subsidiary in 2023. In September 2024 it signed a cooperation memorandum with the Slovenian company PharmaHemp, in Ljubljana and with the Slovenian economy minister present, to develop and produce advanced patches containing purified cannabis extract, spanning hydrocolloid, plastisol and microneedle formats (Hankyung, 2 Sept 2024). The company committed roughly KRW 10 billion in total, split between about KRW 4 billion of equipment, about KRW 4 billion to purchase a plant, and the balance on people (Newstomato). KOTRA reported the production plant as planned for Maribor.

Separately, T&L launched its own skincare brand Illumiel, with Derma Moisture and Clear Skin lines, in 2023 (Dailian, 2023), and has discussed a COMLAX LED patch home beauty device aimed at China (pharm.edaily, 9 Dec 2024).

Why it is a segment. Different geography, different regulatory regime, different product class, and, in the CBD case, a legal framework that does not exist in Korea. The company had to build a European entity because it could not do this work at home.

How it fits. This is the diversification option, not a business yet. It is the clearest evidence of management's stated intent to be more than a supplier to one American brand.

Segment summary

3. Products and business detail

The full catalogue

Wound dressing, hydrocolloid

• RenoCare Hydrocolloid Dressing (Standard) and (Thin): the flagship own-brand occlusive dressings, for light wounds and abrasions. The thin variant is the one that reads as almost invisible on facial skin, which is what makes the format work as a consumer product.
• RenoCare Bee and related SKUs: variants in the same family.
• Trouble-care / acne patches: the ODM line. Multiple dot diameters on a carrier sheet. Sold as Mighty Patch by Hero in the US and Europe. This is the single largest product family in the company.
• Hydrocolloid roll stock: raw material sold to other converters, both domestically and to export customers. This is the business that generates the above-60% domestic raw-material share figure quoted by trade listings, and it matters because it means T&L supplies some of its own downstream competitors.

Wound dressing, non-hydrocolloid

• RenoFoam / RenoFoam A: polyurethane foam dressings for higher-exudate and deeper wounds and burns, sold in standard sizes such as 10x10cm multi-packs through medical distributors.
• RenoCare Alginate Dressing: calcium alginate for cavity and heavily exuding wounds.
• Hydrogel dressings: for dry or necrotic wounds where you need to add moisture rather than absorb it.
• Silicone gel scar dressings: post-surgical and post-burn scar management.

Microneedle

• Dissolving microneedle acne patches, ODM to Hero for the US and to Dongkook Pharmaceutical domestically under the Madeca ArcQ Spot Patch name.

Orthopaedic

• Cast and splint fixation materials, the 1999-vintage line.

Chemical materials

• Waterborne polyurethane dispersions, waterborne urethane-acrylate, waterborne acrylic polyol, waterborne polyisocyanate hardeners, functional additives, urethane foam.

Consumer brand

• Illumiel: T&L's own skincare brand, launched 2023, with a Derma Moisture line and a Clear Skin line built around skin-barrier and antibacterial claims.

Pipeline and adjacent

• Haemostatic agents and transdermal delivery systems using microneedles, both flagged as development directions at the time of the 2020 IPO.
• CBD-loaded hydrocolloid, plastisol and microneedle patches, with PharmaHemp, from Slovenia.
• COMLAX LED patch home beauty device, targeted at China.

What makes it hard to make

Three separate barriers, and it is worth separating them because they fail differently.

Formulation. Hydrocolloid is a composite whose properties are a compromise across at least twenty variables. Getting a sheet that absorbs enough without turning opaque and lifting at the edges, sticks to facial skin overnight without leaving residue, and does that consistently across a production lot, is empirical work. You cannot buy the answer; you buy the material from someone who already has it, which is exactly the business T&L is in.

Conversion at yield. Coating a uniform layer at web speed, then die-cutting dots out of it at a yield that survives a mass-retail price point, is a manufacturing problem with real learning-curve economics. This is where scale compounds.

Regulatory qualification. Wound dressings are regulated medical devices in every market that matters, and acne patches sit on a moving line between device and cosmetic depending on the claim and the jurisdiction. Selling into the US requires FDA registration and listing, and OTC drug pathways where an active is present. Selling into the EU now requires compliance with the Medical Device Regulation, which is materially more onerous than the directive it replaced. Korea requires MFDS approval. Each registration is site-specific and product-specific, so a customer who wants to move to a different supplier is not just re-sourcing a part, they are re-registering a product. At IPO T&L described approvals in ten or more countries; the trouble-patch line went from availability in 6 countries to 46 between roughly 2018 and 2024 (pharm.edaily, April 2024), with the company positioned for around 50 by late 2023 per a Research Alum note reported in Financial News, 5 Dec 2023.

Manufacturing footprint

• Anseong plant, Gyeonggi Province: research, quality and production. This is the operating heart of the company. Anseong's city-level wound-dressing export data is granular enough that analysts use it as a monthly proxy for T&L shipments, which tells you how much of that city's exports T&L represents.
• Headquarters, Yongin, Gyeonggi Province: sales and forward-looking research.
• Slovenia (Maribor): the planned European CBD patch facility, funded by the roughly KRW 10 billion commitment described above.

Capacity, and the shape of the expansions

Capacity at T&L is disclosed and discussed in revenue-equivalent terms rather than in units, so the sequence is best read as a series of step changes rather than a level:

• Prior to 2021, nameplate capacity supported a substantially smaller business.
• A March 2021 Anseong expansion lifted it by roughly half again.
• A further expansion begun in December 2021 was targeted for full operation from Q2 2022, with the CEO stating in February 2022 that the new line would produce microneedle products first from April, with haemostatic agents and others following sequentially (Hankyung, 21 Feb 2022). On the same occasion the company indicated that with overtime the expanded plant could support materially more output than the regular-hours nameplate.
• In H1 2024, overall wound-dressing capacity was raised by roughly a quarter, and microneedle capacity was doubled, targeted operational for July-August 2024 (pharm.edaily, April 2024).

The pattern is worth naming: T&L expands ahead of a specific customer commitment, not speculatively, and the expansions are usually announced with the customer or product they are for.

Milestones

4. Customers

Who buys

Three distinct customer types, with radically different economics.

1. The consumer brand owner (the whole story). Hero Cosmetics, and since September 2022 its parent Church & Dwight. Hana Securities' April 2026 note put this single relationship at roughly 66% of T&L's total sales (Newspim, 14 April 2026). T&L is described as the sole vendor of acne patches to Hero for the US and Europe under an exclusive supply arrangement.

2. Pharmaceutical and medical distribution partners. Around 50 domestic and international companies. Named examples include JW Choongwae Pharmaceutical, Daewoo Pharmaceutical, Hangang Sacred Heart Hospital, the German dressing manufacturer Lohmann & Rauscher, and 3M, with which a supply contract was already in place at the time of the 2020 IPO (iTooza, November 2020). Domestically, Dongkook Pharmaceutical carries the microneedle line.

3. Industrial coatings customers for the chemical materials segment.

Who inside the customer decides, and on what

For the consumer brand, the buying decision sits with a brand and supply-chain function, not a clinician. The criteria are: does the material perform on consumer-perceptible attributes (does the patch flatten the spot overnight, is it invisible, does it stay on), can the supplier hold cost at a price point that survives US mass retail, can it hold quality across a production lot at the volume Target and Walmart require, and is it already registered so the product can be sold now. Sales cycles here are long at initiation and then effectively permanent: once a formulation is locked and the product is registered, re-sourcing means re-doing the consumer testing and the regulatory work on a product that is currently the category leader.

For the pharma and hospital channel, the decision runs through regulatory affairs and procurement, the criteria are clinical evidence, MFDS or CE or FDA status, and price against a reimbursement schedule, and the cycle is measured in quarters.

Why they choose T&L

Specifically: T&L owns the material. A brand that buys finished patches from a converter is one formulation change away from a product it did not ask for. A brand that buys from T&L is talking to the company that makes the hydrocolloid, which means changes are possible and the cost structure has one fewer margin stack in it. The company's own framing is that it can synthesise and produce from raw material onward, which gives it cost competitiveness against companies that buy compound.

Second: T&L is already qualified in the markets that matter, in a category where regulatory registration is site-specific.

Third, and this is underrated: scale on a specific product form. There are very few facilities anywhere set up to die-cut and pack hydrocolloid dots at the volume US mass retail consumes.

Switching costs

High but not absolute, and worth being precise about the mechanism.

• Regulatory: FDA registration and, in the EU, MDR conformity are tied to the manufacturing site. A change of manufacturer is a regulatory event, not a purchasing decision.
• Formulation: the finished product's consumer-perceptible behaviour is the formulation. A different supplier produces a different product, and the risk of that lands on a brand that is currently number one in its category.
• Qualification and validation: the receiving brand has to re-validate, re-test and re-run stability.
• Capacity: even if a brand wanted to move, the set of facilities that can absorb Mighty Patch volumes at short notice is small.

The counter-argument is real: a hydrocolloid dot is not a semiconductor. Church & Dwight is a sophisticated buyer with the resources to dual-source, and the exclusivity that ran to December 2024 has lapsed. The lock-in is meaningful, but it is not the kind that lasts forever without being re-earned on price and service.

Concentration

This is the defining fact about T&L as an investment. Roughly two-thirds of revenue runs through one brand owned by one US consumer-goods company. The company has explicitly targeted reducing this (Finance Scope, 10 Oct 2025).

Is concentration a risk or a quality signal? Both, and the 2025 experience settles the argument. It is a quality signal in the sense that being the sole supplier to the category leader in a growing US category is not something you win by accident. It is a risk in the sense that when Church & Dwight decided to work down channel inventory in 2025, T&L's revenue fell hard for reasons that had nothing to do with consumer demand for the product it makes. Hana's April 2026 note recorded that the customer's inventory normalisation concluded in February 2026 with exports recovering from March.

The asymmetry is the point: T&L absorbs the volatility of the customer's working-capital decisions and does not participate in the retail margin.

Contract structures

The March 2022 Hero contract is the clearest disclosed template and it is instructive. Value approximately KRW 109.3 billion, running from March 2022 to December 2024, covering microneedle patches and trouble-care patches for the United States and Canada. Hero received exclusive sales rights in those markets, and in exchange committed to annual minimum purchases of $25 million in 2022, $30 million in 2023 and $35 million in 2024, with the exclusivity forfeited if the minimums were not met (Pharm News, 18 Mar 2022). T&L described the headline value as an aggregate covering multiple products.

That is a well-constructed contract from T&L's side: it converts an exclusivity grant into a volume floor. Its expiry at the end of 2024 is why T&L was subsequently free to pursue broader distribution, including through 3M.

The rest of the book is a mix of ODM programmes with rolling forecasts, raw-material roll sales, and spot distributor business. Revenue predictability is therefore high in aggregate and poor in any given quarter, because it depends on when one customer chooses to place orders against a stock position you cannot see.

5. Competitive landscape

The honest framing: T&L competes in two different industries at once, and it is a different kind of company in each.

In advanced wound care, it is a small Korean specialist against a global oligopoly. In the consumer acne patch category, it is not really a competitor at all: it is the arms dealer. The brands fighting for shelf space are Hero, Starface, COSRX, Rael, Peace Out and ZitSticka, and T&L makes the product for the biggest one. When people describe T&L as a market leader, this distinction is usually the thing being elided.

Advanced wound care

The global category is concentrated. Market research puts 3M, Smith+Nephew, Mölnlycke, ConvaTec and Coloplast at roughly 55% of the total between them (GM Insights, advanced wound care). These companies compete on clinical evidence, hospital sales forces, and reimbursement positioning. T&L does not compete with them in that arena. It sells into their world as a material and ODM supplier, and 3M has been a T&L customer since at least 2020.

Korean domestic wound care

The domestic moist-dressing market is estimated at around KRW 80 billion and is crowded with pharma-branded products: Medifoam (Genewel, whose parent is Dongsung Chemical, per pharm.edaily, 21 Jan 2025), Easyderm (Daewoong Pharmaceutical, launched 2007), Meditouch (Ildong), Duoderm (Boryung), Solsol Plus (Chong Kun Dang), and Hi-Mom Scar (JW Choongwae). Nico Medical, founded 2010, claims to have been the first to develop and launch a domestic hydrocolloid dressing and acne patch and states it has held the domestic number one sales position since.

The Genewel comparison is the sharpest available benchmark because the two companies are close analogues that diverged. Both are Korean advanced-dressing specialists with strong material technology. Between 2018 and 2023, per the pharm.edaily comparison, Genewel grew roughly 50% cumulatively while T&L grew roughly 340%. The article's own conclusion is that the difference was the overseas partner: T&L found Hero in 2018 and rode it into Church & Dwight's distribution, while Genewel's 2014 licensing arrangement with Mundipharma for Asia-Pacific, Latin America, the Middle East and Africa stalled after Mundipharma restructured in 2022, and Genewel ended the arrangement outside Korea in 2024 and began rebuilding regional partnerships directly.

There is a fact here worth stating carefully and not over-reading. Per the Business Post profile, Choi Yoon-so worked at Dongsung Chemical's central research laboratory from 1992 to 1998 before founding T&L; per pharm.edaily, Genewel is a Dongsung Chemical company. The two facts come from separate sources and are stated as such. Nothing in the sources reviewed characterises the relationship between the companies beyond that.

Microneedle

Raphas (KOSDAQ: 214260) is the most visible listed Korean microneedle specialist, with a proprietary droplet-extension moulding approach it argues is simpler and more scalable than alternatives, an FDA-registered own-brand OTC acne patch, and a microneedle cosmetics ODM business. Daewoong Therapeutics has its own microneedle platform. This is the segment where T&L is least clearly advantaged: it is a capable second entrant bundling microneedle onto existing customer relationships, not the deepest technology holder.

The competitor table

Market caps are peer-size references only, taken from the dates shown; they move.

Barriers to entry

Moderate to high, and unevenly distributed.

• Formulation know-how: high. This is empirical, accumulated, and not licensable off the shelf.
• Regulatory registration: high, and rising. EU MDR raised the cost of being a small dressing manufacturer in Europe considerably.
• Reference customer: very high in practice. A new entrant cannot win Church & Dwight without an existing track record at that volume, and cannot get that track record without a customer of that size.
• Capital: moderate. Coating and die-cutting lines are not semiconductor fabs.
• Cost position: this is where the barrier is thinnest. Chinese and other Asian converters can make a hydrocolloid dot. What they generally cannot do quickly is hold consistency at Western retail volumes with Western regulatory registrations against a brand owner who will not accept a product change.

Market share and structure

In Korean hydrocolloid raw material, third-party trade sources place T&L above 60% share. In the Korean finished moist-dressing market it is one of several branded competitors and has been described as a domestic number two by revenue share in some years, with the growth coming from export. In the global consumer acne patch category, T&L's share is best understood as the manufacturing share behind the leading brand rather than a share it owns.

Structural shifts

Three are live. First, the acne patch category is broadening from patches into adjacent acne products: Church & Dwight has been explicit that facial cleansers represent about 30% of the total acne category and launched a three-SKU Hero cleanser line nationally in mid-2026 (Church & Dwight Q1 2026 earnings call, 1 May 2026). That is category growth T&L does not participate in. Second, geographic expansion of the category into Europe and Asia is running ahead of the US, which is where T&L's growth is now coming from. Third, tariffs have inserted a new cost between a Korean factory and a US shelf, and the sharing of that cost is now a live commercial negotiation.

Where T&L is strong, and where it is exposed

Strong: material ownership, cost, regulatory footprint, and an incumbency at the category leader that is genuinely hard to dislodge in the short run.

Exposed: it does not own the consumer relationship, it does not own the brand, it does not set the price on the shelf, it does not decide when inventory gets rebuilt, and it is not in the adjacent products the category is expanding into. That is a real business with real returns. It is not a moat in the sense of controlling its own demand.

6. Industry

What drives demand

Advanced wound care demand comes from population ageing, diabetes prevalence and the associated chronic ulcer burden, surgical volumes, and the slow clinical migration from dry gauze to moist-environment dressings. It is a healthcare category: growth is steady, driven by demographics, and largely insensitive to consumer sentiment.

Consumer acne patches are a different animal. Demand comes from acne prevalence in a young population, the normalisation of visible skincare as a category (a hydrocolloid dot worn openly in public would have been unthinkable as a product in 2010), K-beauty's global distribution, social media discovery, and mass-retail shelf space. It is a consumer category: growth is faster, driven by marketing and distribution, and it is sensitive to consumer spending and to the inventory decisions of the retailers and brand owners in between.

T&L is a healthcare-regulated manufacturer whose revenue behaves like a consumer supplier's. That mismatch explains most of what happens to its results.

Size and growth

• Advanced wound care: valued at over $12.6 billion in 2025, growing at around 6.2% CAGR toward roughly $23 billion by 2035 (Research Nester). The advanced wound dressing sub-segment is projected from $8.66 billion in 2025 to $16.59 billion by 2035, a 6.71% CAGR (Market Research Future).
• Hydrocolloid acne patch: valued at $1.14 billion in 2025, with a 10.4% CAGR (Archive Market Research). Within the broader anti-acne dermal patch category, hydrocolloid formats hold roughly 81% share (GM Insights).
• Microneedle: projected from $722 million in 2022 to $1.203 billion by 2030, roughly 6.3% CAGR, per the market data cited in The Scoop's analysis.
• Korean moist dressing market: roughly KRW 80 billion, per Medical Today.

The relevant observation: T&L's core end market grows at roughly 10%, materially faster than the clinical wound care market it is technically part of, because the consumer acne patch is a category-creation story rather than a share-shift story.

Where T&L sits in the supply chain

Upstream of the brand, downstream of the base chemicals. It buys commodity polymers and hydrophilic additives, synthesises and compounds the functional material, converts it into finished sterile product, and hands it to a brand owner who does the marketing and distribution. In the parts of the business where it sells hydrocolloid roll stock, it sits one step further upstream and supplies converters who are, in the finished-product market, its competitors.

Value capture along that chain is unequal. The brand owner captures the retail margin and the consumer relationship. T&L captures a manufacturing margin, which is high in absolute terms for a manufacturer because the formulation is proprietary, but it is a manufacturing margin nonetheless.

Import substitution

This runs the opposite way from most emerging-market industrial stories. Korea was an importer of hydrocolloid until T&L developed it domestically in 2007, and the company's early growth was import substitution inside Korea. The subsequent phase has been the inverse: Korea became the export source, and the substitution is now happening in the customer's supply chain, where a US brand chooses Korean-made material over Western-made or Chinese-made alternatives. That is a more fragile position than domestic import substitution, because it can be undone by tariffs or by a customer's near-shoring decision.

Regulation

• Korea: MFDS medical device approval for dressings; separate pathways where a cosmetic claim is made.
• United States: FDA device registration and listing; OTC monograph pathways where an active drug ingredient is present. Notably, a plain hydrocolloid patch with no drug active is regulated more lightly than a benzoyl-peroxide microneedle patch, which is a drug product. This is a live distinction as the category moves toward actives.
• European Union: the Medical Device Regulation, which raised conformity assessment burden versus the prior directive and is a genuine barrier for small manufacturers.
• Cannabis extract: the Slovenia project exists specifically because the regulatory framework for CBD-containing topical products exists in the EU and does not in Korea.

Cyclicality

The clinical dressing business is close to non-cyclical. The consumer patch business is cyclical in a specific and unusual way: it is not exposed to the economic cycle so much as to the retail inventory cycle and now to trade policy. 2025 demonstrated both. Church & Dwight worked down channel inventory, and T&L's shipments fell far more than end-consumer demand did. Simultaneously, US tariffs on Korean goods arrived and, per Sangsangin Securities' September 2025 note, T&L and its US distributor agreed to hold the consumer price and share the margin loss, which compressed both the export price and the cost ratio (Asia Economy, 17 Sept 2025).

That is the shape of the cyclicality: a whipsaw driven by decisions taken in New Jersey and Washington, transmitted to a factory in Anseong.

Tailwinds and headwinds

Tailwinds: a hydrocolloid acne patch market compounding at roughly 10%; category expansion into Europe and Asia where penetration is far below the US; the acne category's own low household penetration (Church & Dwight noted Hero at roughly 10% household penetration versus roughly 30% for the acne category overall on its Q1 2026 call, which is a statement about headroom); demographic demand for advanced wound care; the continuing global pull of K-beauty manufacturing.

Headwinds: tariff friction on Korea-to-US goods; a category attractive enough to invite private-label and low-cost Asian entrants; EU MDR compliance cost for smaller manufacturers; and the structural reality that value in consumer categories accrues to brands, and brands eventually think about vertical integration.

7. Growth triggers

Sourced from the six reporting periods listed at the top and the disclosures, IR events and management statements attached to them. T&L publishes no call transcripts, so each item below is tagged to the specific filing, report or dated statement it comes from.

• Key-customer inventory correction completed in February 2026, exports recovering from March. Hana Securities' note published 14 April 2026, written off company contact, states the primary customer's inventory normalisation concluded in February and exports recovered from March, with Q2 2026 expected to show normalised shipments (Hana Securities note via Newspim, 14 Apr 2026, covering the FY2025 / Q1 2026 window). Repeated: Sangsangin Securities had guided the same recovery from Q1 2026 in its FY2025 review, and Kiwoom Securities confirmed the recovery had landed after the Q2 2026 release.

• Hero/C&D Asia entry via China, Japan and Singapore during 2026, with regulatory approvals in the final stage and order placement expected within the year. Flagged around the Q1 2026 reporting window and repeated in the April 2026 Hana note. This is the single largest identified new-volume trigger.

• European hydrocolloid volumes to exceed US volumes. Following the H1 2025 report, Shinhan Investment Securities estimated European revenue growth of more than double in Q2 2025 and projected that 2026 export volumes to Europe would exceed those to the US; by July 2025, UK, France and Germany combined hydrocolloid exports had reached roughly half the US level (Daily Invest, 22 Aug 2025). Repeated in the Q1 2026 window, where Europe-bound Mighty Patch shipments through C&D to Germany, the UK and France were again identified as the growth leg.

• Expansion into new countries through collaboration with 3M. Identified as a growth driver following the Q2 2026 release by Kiwoom Securities (Hello T, 19 Aug 2026). 3M has been a T&L supply customer since a 2020 contract; the significance of the 2026 framing is that it is now positioned as a route into new geographies rather than a single supply line. Repeated: customer and geographic diversification through 3M's global network was also identified in October 2025 (Finance Scope, 10 Oct 2025).

• New cosmetics-company contracts becoming visible, reducing Hero/C&D dependence. Stated in the Q3 2025 window (Finance Scope, 10 Oct 2025), which also recorded that raw-material supply contracts with major foreign firms were under development and that global cosmetics partnerships on microneedle were expected by year end (Sangsangin Securities, September 2025).

• CBD patch production in Slovenia and first revenue from cannabis-extract products. A company representative stated that CBD extract-based products would be developed, that production facilities in Slovenia would be completed by year end, and that revenue from the related products would be generated the following year. The programme spans hydrocolloid, plastisol and microneedle formats under the PharmaHemp memorandum signed in Ljubljana in September 2024.

A T&L representative, quoted around the December 2024 outlook coverage: the company plans to complete the Slovenian production facility by year end and generate revenue from cannabis-extract products from the following year, applying the extract across hydrocolloid, plastisol and microneedle formats.

This item has been repeated across multiple periods with a moving timeline, which Section 9 addresses directly.

• COMLAX LED patch home beauty device for the China market. Identified alongside the CBD programme as a new growth driver in the December 2024 outlook coverage (pharm.edaily, 9 Dec 2024).

• Microneedle capacity doubled and operational from July-August 2024, supporting the next leg. Announced in the April 2024 window and referenced since as the enabler for microneedle growth (pharm.edaily, 15 Apr 2024). Domestically the line is commercialised through Dongkook Pharmaceutical as the Madeca ArcQ Spot Patch.

• Gross margin sustainability above prior peaks. Following the Q2 2026 release on 14 August 2026, Kiwoom Securities recorded that T&L had set a company-record gross margin in the quarter, achieved without tariff refunds, and expected gross margin to hold at elevated levels in subsequent quarters (Hello T, 19 Aug 2026). This is the most recent forward statement in the set.

Trigger summary

8. Key risks

1. Single-customer concentration, and the specific mechanism by which it hurts

Roughly two-thirds of revenue depends on one brand owned by one company. The mechanism that matters is not "Church & Dwight cancels", which is unlikely in the near term given the regulatory and formulation lock-in. The mechanism is the one that already happened: Church & Dwight decides to reduce channel inventory, and T&L's order book collapses while end-consumer demand is fine.

This is worse than ordinary customer concentration because T&L cannot see the inventory. It sees purchase orders. In 2025 the correction ran long enough that FY2025 revenue and operating profit both fell year on year, and it was not resolved until February 2026. The company had no lever to pull. Calibration: high probability of recurrence, moderate severity, and effectively unhedgeable while concentration stays at this level.

2. T&L does not own the consumer relationship

The strategic version of risk 1. Every dollar of brand equity built by the Super Bowl advertising and the Amazon ranking accrues to Hero, not to T&L. If Church & Dwight ever decides to dual-source, near-shore, or vertically integrate, T&L's negotiating position is its formulation and its cost, and nothing else. It has no consumer who would notice.

The evidence that this is not theoretical is in the tariff episode: when a cost shock arrived, the outcome was that the consumer price was held and the margin loss was shared between T&L and the distributor (Sangsangin Securities, September 2025). A supplier with pricing power does not share a tariff. Calibration: moderate probability over a multi-year horizon, high severity.

3. Tariffs on Korea-to-US goods

Direct and already realised. US tariffs on Korean goods inserted a cost between the Anseong plant and the US shelf in 2025. The commercial response was to hold the consumer price and split the pain, which reduced both the realised export price and the gross margin. The Q2 2026 record gross margin was explicitly noted as achieved without tariff refunds, which implies refunds are a live variable that could swing results in either direction.

Calibration: high probability of continued exposure, moderate severity. The offsetting argument, made by Sangsangin in its September 2025 note, is that even with tariffs the volume growth story survives, because the tariff hits profitability per unit rather than demand.

4. Exclusivity has lapsed, and it cuts both ways

The March 2022 contract's exclusivity, with its $25m/$30m/$35m annual minimums, ran to December 2024. That expiry is what freed T&L to broaden distribution through 3M and other partners. It also removed the contractual volume floor. There is no longer a disclosed minimum purchase obligation protecting T&L's downside at its largest customer. Calibration: certain (already happened), moderate severity, partially offset by diversification.

5. The category is expanding into products T&L does not make

Church & Dwight has said facial cleansers are roughly 30% of the total acne category and launched a Hero cleanser line nationally in mid-2026. That is the brand growing into adjacent revenue that runs through a different contract manufacturer entirely. If the acne category's growth increasingly comes from formats outside patches, Hero can grow without T&L growing. Calibration: high probability, moderate severity, and structurally under-discussed.

6. Microneedle is contested, and T&L is not the deepest technology holder

Raphas has a dedicated microneedle platform, its own FDA-registered US branded acne drug patch, and an established microneedle cosmetics ODM business. Daewoong Therapeutics has a separate platform. T&L's microneedle position rests substantially on being able to sell it to customers who already buy hydrocolloid. If the microneedle acne category moves toward drug-actives, where the regulatory and clinical burden is higher, the advantage shifts to whoever has the drug pathway. Calibration: moderate probability, moderate severity.

7. Slovenia, CBD and execution risk on diversification

The Slovenia project is a foreign greenfield in a product category with a regulatory framework T&L has no operating history in, executed by a company whose entire manufacturing competence sits in one Korean plant. The commitment is roughly KRW 10 billion, which is not large, but the management attention cost and the timeline slippage risk are real, and the timeline has already moved across reporting periods. Calibration: moderate probability of disappointment, low direct financial severity, meaningful signalling severity because it is the flagship of the diversification narrative.

8. Succession and governance

In late December 2025, the founder gifted roughly 10.45% of the company, around 852,520 shares, to his eldest son, who was simultaneously promoted to Managing Director. The transfer happened when the share price was about 41% below its prior-year peak, and the company was asked publicly whether the timing was tax-driven.

"It is not true that this was a low-point gift for tax-saving purposes. The share price decline was largely driven by the business environment, including last year's weak revenue."

• T&L official, quoted in the Governance Watch report carried by Daum, 12 Jan 2026

The risk is not the gift itself, which is a normal succession mechanic in Korean founder-controlled companies. The risk is what a controlling family optimising for a low transfer valuation does to the incentive to communicate optimistically, and the more general risk of second-generation management transition at a company whose entire competitive position rests on technical depth accumulated by the founder. Calibration: low probability of acute damage, but a persistent governance discount factor.

9. Currency

Not a generic risk here. T&L's cost base is almost entirely won-denominated and around three-quarters or more of revenue is export, so the won/dollar rate flows almost directly to profit. Sangsangin's September 2025 note listed exchange-rate decline alongside tariffs and weak US consumption as the drivers of the downgrade. A sustained won appreciation would compress margins with no operational offset available. Calibration: high probability of continued exposure, moderate severity.

10. Manufacturing concentration in a single plant

Effectively all production sits in Anseong. A fire, a regulatory suspension, or a prolonged outage there would stop the company. Calibration: low probability, catastrophic severity.

9. Walk the talk

The six reporting periods used: Q1 2025 (mid-May 2025), Q2/H1 2025 (14 Aug 2025), Q3 2025 (14 Nov 2025), FY2025 (annual report 18 Mar 2026), Q1 2026 (15 May 2026), Q2/H1 2026 (14 Aug 2026). The most recent is 22 days old.

A necessary caveat before the assessment: because T&L holds no public earnings calls, there is no body of quarter-by-quarter management guidance to score. What can be scored is the set of dated, attributable commitments the company has made in filings, contract disclosures, IR briefings and press statements, and what happened to them. That is a thinner evidence base than a six-transcript series, and the conclusions below are calibrated accordingly. Where the commitment came from a sell-side note written off a company meeting rather than from the company's own mouth, that is stated.

Starting point: 2024, the promises going into the window

Entering the period, management's public commitments were specific and numerous. The April 2024 statements set out a capacity plan: overall wound-dressing capacity up by roughly a quarter in H1 2024, and microneedle capacity doubled and operational by July-August 2024. The December 2024 outlook coverage added two named diversification programmes: medical cannabis patches launching from Slovenia in H1 2025, and the COMLAX LED beauty device for China by end-2025. Alongside this, the company had disclosed that Hero's exclusivity restrictions would lapse in 2024, freeing broader distribution.

Capacity was delivered. The microneedle capacity doubling landed on schedule, and microneedle revenue on the FY2023 cumulative basis had already more than doubled year on year before the expansion. This is the clearest kept promise in the set, and it fits the pattern: T&L's operational commitments about its own plant have generally been met.

Q1 2025: the first crack

The year opened with consensus expecting substantial growth. What arrived instead was a Q1 in which US exports were pulled forward ahead of anticipated tariffs, flattering the quarter and setting up a worse Q2. Sangsangin's July 2025 note described exactly this: first-quarter US exports surged ahead of tariffs, and combined with won weakness, that dampened Q2 (Asia Economy, 8 July 2025). Management did not, in the sources reviewed, warn in advance that Q1 strength was a pull-forward. That is not a broken promise, but it is an absence of proactive communication about a known distortion.

Q2/H1 2025: the guidance goes down, twice

This is the period where the record turns. Sangsangin cut its target on 8 July 2025 ahead of the Q2 release, citing tariffs, and cut again on 17 September 2025 after it. The reported reality for Q2 2025 was a sharp year-on-year decline in both revenue and operating profit. The mechanism, per the September note, was that T&L and its US distributor agreed to hold the consumer price and share the tariff-driven margin loss, which cut both export value and gross margin.

Two things about this deserve credit and one does not. It deserves credit that the deterioration was explained precisely and consistently by the analysts closest to the company, which implies management was communicating the mechanism rather than obscuring it. It deserves credit that the European leg was flagged as genuinely accelerating in the same period, with Shinhan estimating Europe growing more than double in Q2 and projecting European volumes to exceed US volumes in 2026, a call that has broadly held. What does not deserve credit is that the CBD patch launch promised for H1 2025 did not arrive in H1 2025, and the goalposts moved to Slovenian facility completion by end-2025 with revenue the following year.

Q3 2025: consistent messaging, unchanged reality

Cumulative nine-month 2025 showed modest revenue growth against a meaningful operating profit decline. The forward message was consistent and repeated: US inventory adjustment completes by end-2025, US exports normalise from Q1 2026. The October 2025 framing added the strategic commitment that most matters, stated plainly: reduce dependence on Hero and C&D, expand through 3M's global network, and bring new cosmetics-company contracts visible (Finance Scope, 10 Oct 2025).

That is a promise with a scoreable outcome. As of the Q2 2026 release, 3M collaboration is being cited as a growth driver by Kiwoom, but the customer concentration figure Hana used in April 2026 was still roughly 66%. The diversification is directionally underway and quantitatively unproven.

FY2025: the year missed, and the dividend response

FY2025 closed with revenue and operating profit both down year on year. Against the consensus that had existed entering 2025, this was a substantial miss. It was a miss driven by two external factors (tariffs, a customer inventory decision) rather than by an operational failure, and the company said so.

What management did next is the most informative single act in the six-period window: with earnings down, on 23 December 2025 the board doubled the dividend, from 750 won to 1,500 won per share (Bloter, 23 Dec 2025). Raising the payout materially into a weak year, and doing so with the record date at the immediately following year end, is a costly signal. It is consistent with management believing the weakness was transient.

It is also fair to note the awkward adjacency: the same December window in which the dividend doubled was the window in which the founder transferred roughly 10.45% of the company to his son at a share price about 41% below the prior-year peak. Both facts are true, both are disclosed, and the company has publicly rejected the tax-timing reading.

Q1 2026: the recovery arrives, on the stated timetable

Q1 2026 revenue and operating profit were still down year on year, but sequentially the hydrocolloid export line inflected hard, and April Anseong wound-dressing exports crossed $10 million for the first time since January 2025, with 82% going to the US. Hana's 14 April 2026 note recorded the key customer's inventory adjustment as concluded in February, with exports recovering from March, and normalised shipments expected from Q2.

Cross-reference that against what was promised in Q3 2025: "US inventory adjustment completes by end-2025, exports normalise from Q1 2026." The actual outcome was completion in February 2026 and recovery from March. That is roughly a one-to-two-month slip on a two-quarter-ahead call, which counts as delivered.

Q2/H1 2026: delivered, and then some

The 14 August 2026 release produced a company-record gross margin, achieved without tariff refunds, with operating profit growing sharply year on year and revenue coming in ahead of the consensus estimate. Kiwoom raised its target price modestly and guided gross margin to stay at elevated levels (Hello T, 19 Aug 2026).

Promise versus outcome

The assessment

T&L's management is reliably accurate about its factory and unreliably accurate about its new ventures.

Every commitment involving the Anseong plant, capacity, timing of line commissioning, and the mechanics of its existing customer relationships has been met or nearly met. The two-quarter-ahead call on when the customer inventory correction would clear was correct to within about a month, which is a genuinely hard forecast to get right and implies real visibility into the customer.

Every commitment involving a new geography, a new product category or a new legal regime has slipped. The Slovenia CBD launch was promised for H1 2025 and, as of the most recent reporting period, the sources reviewed do not show it generating revenue. The China LED device promised for end-2025 has not been restated. The diversification-away-from-C&D promise made in October 2025 is directionally live and quantitatively unmoved.

This is neither overpromising nor sandbagging. It is a specific and quite common pattern: an engineering-founded company that is precise about the thing it controls and optimistic about the thing it does not. The dividend doubling into a down year is a genuine credibility marker in the other direction, because it is expensive and hard to fake.

The practical implication for a reader: treat T&L's statements about volumes, capacity and its existing customer as reliable. Treat its statements about CBD, China, LED devices and new-category diversification as options with no reliable timeline.

10. Shareholder friendliness index

Dividends. T&L has paid a rising ordinary dividend every year in the window and accelerated it sharply in the most recent one. DPS was 550 won for FY2023 (board resolution 20 December 2023, total approximately KRW 4.44 billion), 750 won for FY2024 (resolution 20 December 2024, total approximately KRW 6.05 billion, record date 31 December 2024), and 1,500 won for FY2025 (resolution 23 December 2025, total KRW 12.03 billion, record date 31 December 2025, paid 15 April 2026, per Bloter and S-Econ). That is growth, then a doubling. The FY2025 doubling is the unusual data point and it is unusual in the right direction: it was declared into a year in which revenue and operating profit both fell, which took the payout ratio well above the roughly 20% of net income the company had described as its internal target in earlier years (The Bell, 11 Jan 2024). Paying out a materially higher share of a smaller profit is a deliberate signal, not a mechanical formula.

Buybacks and dilution. No treasury-share acquisition programme, trust agreement or cancellation resolution for T&L could be located in exchange announcements, KRX treasury-stock listings, or Korean financial news across the three years to September 2026, and searches specific to the company returned nothing. Note the two-window rule this reflects: for the recent period the finding is a positive absence, and for the older period it rests on the full three-year search just described rather than on any short-window source. Share count over the window changed for one reason only: a 1-for-1 bonus issue resolved in July 2026, with the new shares allocated in early August (the CEO's ownership filing records 7 August 2026 as the acquisition date), taking shares outstanding from 8,035,060 to 16,070,120 (Herald Economy; Digital Today, 10 Aug 2026). A bonus issue funded from share premium is a split, not dilution: no cash was raised and no economic interest was transferred. There is one loose end worth flagging rather than smoothing over: T&L also ran a 1-for-1 bonus issue in June 2021 that created 4,064,000 new shares, which implies roughly 8,128,000 shares afterward, versus the 8,035,060 outstanding immediately before the 2026 issue. That gap of roughly 93,000 shares is consistent with a small treasury-share cancellation somewhere in between, but no acquisition or cancellation resolution supporting it was found, so it is recorded here as unverified rather than presented as a buyback.

Verdict: Returns Capital. Doubling the dividend into a year when profit fell, rather than trimming it, is the single most informative capital-return act in the window, and it was funded from a balance sheet carrying very little debt.

11. Insider activities

Source note. Korea's primary source is DART (dart.fss.or.kr), specifically the 임원·주요주주 특정증권등 소유상황보고서 (Officer and Major Shareholder Securities Holdings Report) and 5% Rule reports. DART's document viewer serves filing content through a frame-based interface that returned only document indexes rather than filing bodies during this research, and the KIND mirror behaved the same way. No MoatMap database block was supplied for this company. The transactions below are therefore taken from Korean financial-media reports that transcribe the individual DART filings, with the filing date and reason as reported, and from the Governance Watch report on the December 2025 transfer. Each is cited to the report that carried the filing. This is a second-hand chain for a primary-source requirement and is disclosed as such.

Recent transactions (last 12 months, most recent first)

Sources: Digital Today, 10 Aug 2026; Datatooza, 10 Aug 2026; Datatooza, Kim Kang-yong filing; Digital Today, 11 Jun 2026; Governance Watch via Daum, 12 Jan 2026.

Related-party structure as reported in the 11 June 2026 filing, before the bonus issue: Choi Yoon-so 1,926,000 (23.70% of the wider share-equivalent base), Choi Hyun-jun 912,520 (11.23%), Pyun Do-ki, executive, 196,460 (2.42%), Kim Myung-joo, relative, 70,000 (0.86%), Choi Woo-jun, relative, 60,000 (0.74%), Kim Kang-yong, executive, 37,680 (0.46%), Im Sang-hyun, executive, 35,200 (0.43%), Yoon Hyung-soon, executive, 18,610 (0.23%), Yang Hwa-seob, executive, 14,000 (0.17%). Group total 3,270,470 shares, 40.24%. No career or biographical detail beyond role and holding is disclosed in the sources reviewed for any of these individuals, and none is asserted here.

Buys: reading the signal

There were no open-market purchases by any T&L insider in the last 12 months. Searches specifically for on-market insider buying by T&L officers and for owner buying framed as responsible management returned nothing for this company.

The August 2026 increases look like buying in a share-count table and are not. They are the automatic allotment of bonus shares from the 1-for-1 issue, received by every shareholder pro rata at nil cost. Every insider's percentage stake was effectively unchanged. There is no conviction content in these filings at all, and reading them as insider accumulation would be a straightforward misreading of a Korean filing table.

The absence is notable for a specific reason. Through H1 2025 the shares fell hard, the company's own spokesperson acknowledged in January 2026 that the price was about 41% below its prior-year peak, and management was simultaneously telling the market that the customer inventory correction was transient and would clear by Q1 2026. That combination, a management team that believes the weakness is temporary and a price down 40%, is the textbook setup for insider buying. It did not happen. The board expressed its confidence through the dividend instead, which is a real signal but a corporate one paid with company cash rather than a personal one paid with the insiders' own.

Sells: working out the why

There were no open-market sales by any T&L insider in the last 12 months either. The two share movements that reduced a named holder's position were not sales:

• The December 2025 gift is a succession transfer, not a disposal. The founder moved roughly a third of his personal stake, about 852,520 shares or 10.45% of the company, to his eldest son, taking his own holding from roughly 34.15% to 23.70% and lifting the son from 0.74% to 11.23%, making him the second-largest holder. No shares left the family. The reason is disclosed in the Governance Watch reporting and corroborated by the son's simultaneous promotion to Managing Director: this is the opening move of a generational transfer of control.

  The contested part is timing. The transfer took place with the shares roughly 41% below their prior-year peak, which minimises the gift-tax base. Korean gift tax on a listed-share transfer of this size is substantial and is assessed on a market-price average around the transfer date, so the difference between transferring at the peak and transferring 41% below it is a very large number. The company was asked and denied it:

  "It is not true that this was a low-point gift for tax-saving purposes. The share price decline was largely driven by the business environment, including last year's weak revenue."

  • T&L official, Governance Watch report carried by Daum, 12 January 2026

  Both readings are available to a reader and the filing does not settle it. What can be said without speculation is that the transfer was made at a price the family's own subsequent actions suggest they believed was low, since the same board doubled the dividend days later and the recovery they had been forecasting arrived two months after that.

• The June 2026 reduction is an accounting event. Choi Seung-woo ceased to be an officer on 10 June 2026, so his 200,000 shares dropped out of the controlling shareholder's reportable related-party aggregate. The group total fell from 3,470,470 to 3,270,470 for that reason alone. Nothing was traded. Whether he retained, sold or disposed of the shares afterward is outside the reporting perimeter and is not disclosed in the sources reviewed.

Net assessment

Insiders were neither net buyers nor net sellers in the open market over the last 12 months; every reported movement was a bonus allotment, a family succession gift, or a reporting-perimeter change. Ownership is highly concentrated and static: the founder and related parties held about 40% of the company before the bonus issue and hold the same proportion after it.

The activity is concentrated in two people, and the one substantive event is a succession transfer rather than a market transaction. Nothing here signals a change in family commitment; if anything, moving 10% of the company to the next generation while promoting him into the executive ranks signals the opposite, that the family intends to keep control across a generation rather than monetise it.

What is missing is the confirming signal. A management team that was publicly forecasting a Q1 2026 recovery, watching its own stock down more than 40%, and confident enough to double the dividend, still did not buy a single share on market. The dividend carries the message; the personal balance sheets stayed out of it.

Plain-language read: neutral. No selling pressure, no red flag, meaningful insider alignment through a 40% family stake, and a clean succession narrative, but also no personal conviction purchase at a price the family's own actions imply they thought was cheap.

12. Scenarios

Bull case

The 2025 downturn turns out to have been the last time T&L's fortunes were dictated by a single American brand's warehouse.

The Asia launch lands. Hero's regulatory approvals in China, Japan and Singapore complete, orders are placed, and by 2028 the Mighty Patch is a genuinely global product rather than an American one with a European appendix. Europe, which was already growing faster than the US by mid-2025 and running at roughly half US export value by that July, overtakes the US outright and keeps compounding, because European household penetration of the acne patch category starts from a fraction of the American level and the same distribution machine is now pushing it. Each new geography is incremental volume through an Anseong plant whose fixed cost was paid for years ago, which is why the record gross margin set in Q2 2026 proves to be a floor rather than a peak.

Meanwhile the concentration problem quietly solves itself, not by losing Church & Dwight but by growing everything else faster. The 3M relationship, which has existed since 2020 as a supply line, becomes a distribution channel into countries T&L could never have registered in alone. New cosmetics-brand contracts land. Microneedle, with capacity already doubled and a domestic showcase running through Dongkook Pharmaceutical, becomes the second real product line rather than a promising line item, helped by the fact that a brand buying hydrocolloid from T&L can add microneedle without qualifying a new supplier. By the time anyone recalculates, the largest customer is a third of revenue rather than two-thirds, and the same sentence that used to describe a risk now describes a foundation.

Slovenia works. The Maribor facility produces CBD-loaded hydrocolloid and microneedle patches for a European market where the regulatory framework exists and no incumbent has scaled the format, and T&L discovers it owns a category rather than a product. The chemistry that made a pimple patch turns out to be a delivery platform, which is what the founder has been implying since the company started talking about transdermal delivery at IPO.

Base case

The plant runs full, the customer behaves, and the company grows at the rate of its category without changing its shape.

The recovery that arrived in March 2026 continues. US volumes normalise now that the inventory correction is behind them, Europe keeps growing faster than the US, and the Asia launch happens roughly on the timetable management has described, contributing meaningfully in 2027 rather than 2026. Growth lands somewhere near the 20% annual pace management has pointed to, driven by volume through an already-built plant, and gross margins stay at or near the levels set in the first half of 2026 as long as the won and the tariff settlement do not move against them. Neither is under the company's control, so results stay lumpy quarter to quarter even while the trend is up.

Church & Dwight stays roughly two-thirds of revenue. The 3M channel adds countries at the margin, new cosmetics contracts arrive in ones and twos, and diversification is real but slow, because reference customers of Hero's size do not come along often and the alternative customers are individually small. Microneedle grows but stays a supporting line. Slovenia gets built, produces something, and does not move the numbers for several years.

The dividend keeps rising, because that is what this board has done through both a good year and a bad one. The family completes its succession quietly. The company remains what it has been since 2018: an exceptionally well-run contract manufacturer with a genuine materials edge, whose earnings are more volatile than its business, because its order book is someone else's inventory decision.

Bear case

The thing that breaks is not demand. It is position.

Church & Dwight, having absorbed a tariff cost it had to split with its supplier, decides that a hydrocolloid dot sourced from a single facility in Korea is a supply-chain concentration it does not need to carry. It qualifies a second source, perhaps closer to the US market, perhaps simply cheaper. It does not cancel T&L, because the formulation and registrations are real and the transition would be slow. It just splits the volume, and then uses the existence of the second source in every subsequent price conversation. T&L's volumes hold and its margins do not, and the record gross margin of mid-2026 turns out to have been the top of the cycle.

Compounding this, the acne category keeps growing while T&L's share of it shrinks. Church & Dwight has already said cleansers are roughly 30% of the total acne category and launched a Hero cleanser line in 2026. If the brand's growth increasingly comes from formats T&L does not make, then Hero can compound handsomely while T&L's order book flatlines, and the company discovers that being the manufacturing backbone of a brand is not the same as participating in that brand's growth.

The diversification does not rescue it in time. Slovenia slips again, as it has already slipped once from an H1 2025 launch promise. The China LED device, promised for end-2025 and not restated since, stays unmentioned. Microneedle runs into competitors with deeper platforms and, if the category moves toward drug-actives, a regulatory pathway T&L does not have. The new cosmetics contracts materialise but are individually too small to replace a customer that was two-thirds of revenue.

And underneath it, the specific vulnerability the last two years exposed remains unfixed: a single plant, a single dominant customer, a cost base entirely in won against revenue almost entirely in dollars and euros, and no consumer who would notice if the company disappeared. None of those individually is fatal. In a bad sequence they arrive together, and the company spends several years with a full factory, falling margins, and a dividend that becomes harder to justify each year.

Sources: company disclosures and filings via DART and KRX KIND, the T&L corporate site, the IRGO filing and IR calendar for 340570, Church & Dwight investor relations and its Q1 2026 earnings call, Business Post, The Scoop, pharm.edaily, Pharm News, Hankyung, Newspim, Hello T, Asia Economy, Daily Invest, Bloter, Digital Today, Datatooza, Governance Watch via Daum, GM Insights, Research Nester, Market Research Future, Archive Market Research and CompaniesMarketCap.